Amonafide

From Self-sufficiency
Jump to: navigation, search
Amonafide
File:Amonafide.svg
Systematic (IUPAC) name
5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
Identifiers
CAS Number 69408-81-7
ATC code none
PubChem CID 50515
Chemical data
Formula C16H17N3O3
Molar mass 283.325 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Amonafide (originally AS1413) (INN, trade name Quinamed) is a drug that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and DNA intercalators.

It is being developed as an anti-cancer therapy by Antisoma.[1]

As of 2008, it is in Phase III clinical trials. eg In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".


  1. http://www.genengnews.com/news/bnitem.aspx?name=78979622
  2. http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"